Reuben, A., Spencer, C., Prieto, P., , Reddy, S., Miller, J., … Wargo, J. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genomic Medicine, 2. https://doi.org/10.1038/s41525-017-0013-8 (Original work published 2017)

, Spencer, C., Nezi, L., Reuben, A., Andrews, M., Karpinets, T., … Wargo, J. (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)

Khouri, I., Curbelo, F., Turturro, F., Jabbour, E., Milton, D., RL, B. , Jr, … Sharma, P. (2018). Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(5), 1011-1018. https://doi.org/10.1158/1078-0432.CCR-17-2777 (Original work published 2018)

Ariyan, C., Brady, M., Siegelbaum, R., Hu, J., Bello, D., Rand, J., … Allison, J. (2018). Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 6(2), 189-200. https://doi.org/10.1158/2326-6066.CIR-17-0356

Amaria, R., Prieto, P., Tetzlaff, M., Reuben, A., Andrews, M., Ross, M., … Wargo, J. (2018). Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 19(2), 181-193. https://doi.org/10.1016/S1470-2045(18)30015-9

Daver, N., Boddu, P., Garcia-Manero, G., Yadav, S., Sharma, P., Allison, J., & Kantarjian, H. (2018). Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia, 32(5), 1094-1105. https://doi.org/10.1038/s41375-018-0070-8

Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., … Sharma, P. (2018). Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI99760 (Original work published 2018)

Sharma, A., Subudhi, S., Blando, J., Scutti, J., Vence, L., Wargo, J., … Sharma, P. (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)